Pharmaceutical giant Pfizer has been told to pay a record £84.2 million by the British competition watchdog after they hiked up the price of an epilepsy drug by 2,600 per cent.
In 2012, the price of a 100mg packet of the capsules went from £2.83 to £67.50.
Annual spending on the drugs by the NHS rose from £2 million to about £50 million.
US drugmaker Pfizer used to market the medicine under the brand name Epanutin.
But it sold the rights to Flynn, a privately owned British company, in September 2012. It was then debranded, so was no longer subject to price regulation.
Pfizer said the medicine had been losing money so it was forced to consider whether it could continue supplying it.
Pfizer and Flynn, fined £5.2 million, plan to appeal.
Full Content: The Straits Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
PepsiCo Sued Over Alleged Price Discrimination Involving Walmart
Jan 19, 2025 by
CPI
Regulators Approve Conditions for Multibillion-Dollar Oil Mergers
Jan 19, 2025 by
CPI
FTC Reaches Settlement with Private Equity Firm Over Antitrust Allegations in Texas
Jan 19, 2025 by
CPI
FTC Raises Antitrust Concerns Over Big Tech’s AI Partnerships
Jan 19, 2025 by
CPI
MultiPlan and Insurers Move to Dismiss Antitrust Allegations Amid Growing Legal Challenges
Jan 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand